ArticleJournal of experimental pharmacology2025
Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with Defibrotide.
Article in Journal of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute graft-versus-host disease (aGVHD) is a significant cause of death in recipients of allogeneic hematopoietic stem cell transplantation. In this type of graft, the intestine is particularly affected, with the loss of intestinal barrier integrity playing a key role in its onset. In this scenario, the aim of the present research was to evaluate defibrotide, a heparin-like compound, marked for severe veno-occlusive disease, as an innovative therapeutic approach for restoring intestinal barrier integrity using an in vitro model and analyzing aGVHD patients' sera and clinical data. Patients and Methods: Using an in vitro model of colon epithelium, we evaluated the modulation of tight junction proteins after defibrotide treatment, in basal condition or in presence of an inflammatory stimulus, by immunocytochemical and Western blotting analysis. Moreover, the study involved two patients with grade IV acute multisystem GVHD with great gastrointestinal compromission. Patients' sera were collected during the acute phase and remission of intestinal aGVHD and employed for the evaluation of a panel of 27 inflammatory cytokines using a Multiplex approach. Results: Defibrotide treatment significantly increased the protein expression of Zonulin-1 and Occludin (untreated vs treated with 200 μg/mL, p<0.01). In culture conditions mimicking inflammation, defibrotide countered the reduction of Occludin and Claudin-3 while preserving Zonulin-1 levels. Serum cytokine analysis of two patients receiving defibrotide for aGVHD showed significantly higher cytokine levels (IL-7, MIP-1β, IP-10, G-CSF, Eotaxin, IL-6) during the acute phase compared to remission after defibrotide treatment. Conclusion: These findings suggest a potential therapeutic role for defibrotide in managing intestinal aGVHD by improving epithelial barrier integrity and reducing inflammation-related damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.